Vandetanib
Other Protein Kinase Inhibitors
Sold as Zactima · CAPRELSA
- Drug class
- Other Protein Kinase Inhibitors
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 5
Overview
Vandetanib is an active pharmaceutical ingredient in the Other Protein Kinase Inhibitors group (L01EX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 2 | April 30, 2026 |
| GB United Kingdom | MHRA | 2 | April 10, 2026 |
| EU European Union | EMA | 1 | May 29, 2026 |
CACanada· Health Canada
2 products
How to take
and 7 WARNINGS AND PRECAUTIONS; Cardiovascular). 5 Drug-Food Interactions Exposure to CAPRELSA is not affected by a meal. Products and juices containing grapefruit, star fruit, pomegranate, Seville oranges and other similar fruits that are known to inhibit CYP3A4 should be avoided at any time.
6 Drug-Herb Interactions Interactions with herbal products have not been studied. St. John’s Wort is a potent CYP3A4 inducer. PrCAPRELSA® (vandetanib) Page 26 of 47 Protected B / Protégé B Co-administration with CAPRELSA may lead to increased CAPRELSA metabolism, therefore decreased CAPRELSA serum concentrations.
Co-administration with CAPRELSA should be avoided. 7 Drug-Laboratory Test Interactions Interactions with laboratory tests have not been established. 1 Mechanism of Action Vandetanib is a potent and selective inhibitor of vascular endothelial growth factor receptor-2 (VEGFR- 2, KDR), epidermal growth factor receptor (EGFR), and Rearranged during Transfection (RET) receptor tyrosine kinases.
GBUnited Kingdom· MHRA
2 products
Uses
Caprelsa is indicated for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older.
How to take
EUEuropean Union· EMA
1 product
Uses
Caprelsa is indicated for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older.
How to take
Drug interactions
Known interactions involving Vandetanib. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 279. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02378582 · revised April 30, 2026
- [2]MHRA (UK) · PLGB044250762 · revised April 10, 2026
- [3]European Medicines Agency · EMEA/H/C/002315 · revised May 29, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.